Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)
© 2023. The Author(s)..
Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
Wiener klinische Wochenschrift - 135(2023), Suppl 1 vom: 27. Jan., Seite 32-44 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023) |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 28.04.2023 Date Revised 04.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00508-023-02186-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356046443 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356046443 | ||
| 003 | DE-627 | ||
| 005 | 20231226065628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00508-023-02186-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356046443 | ||
| 035 | |a (NLM)37101023 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Clodi, Martin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023) |
| 246 | 3 | 3 | |a Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2023 | ||
| 500 | |a Date Revised 04.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diabetes mellitus Type 2 | |
| 650 | 4 | |a Therapy Glucose lowering | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Abrahamian, Heidemarie |e verfasserin |4 aut | |
| 700 | 1 | |a Brath, Helmut |e verfasserin |4 aut | |
| 700 | 1 | |a Schernthaner, Guntram |e verfasserin |4 aut | |
| 700 | 1 | |a Brix, Johann |e verfasserin |4 aut | |
| 700 | 1 | |a Ludvik, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Drexel, Heinz |e verfasserin |4 aut | |
| 700 | 1 | |a Saely, Christoph H |e verfasserin |4 aut | |
| 700 | 1 | |a Fasching, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Rega-Kaun, Gersina |e verfasserin |4 aut | |
| 700 | 1 | |a Föger, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Francesconi, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Fröhlich-Reiterer, Elke |e verfasserin |4 aut | |
| 700 | 1 | |a Kautzky-Willer, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Harreiter, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Luger, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Resl, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Riedl, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Winhofer, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Hofer, Sabine E |e verfasserin |4 aut | |
| 700 | 1 | |a Hoppichler, Friedrich |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Joakim |e verfasserin |4 aut | |
| 700 | 1 | |a Kaser, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Ress, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Lechleitner, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Aberer, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Mader, Julia K |e verfasserin |4 aut | |
| 700 | 1 | |a Sourij, Harald |e verfasserin |4 aut | |
| 700 | 1 | |a Toplak, Hermann |e verfasserin |4 aut | |
| 700 | 1 | |a Paulweber, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Stechemesser, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Pieber, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Prager, Rudolf |e verfasserin |4 aut | |
| 700 | 1 | |a Stingl, Harald |e verfasserin |4 aut | |
| 700 | 1 | |a Stulnig, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Rami-Merhar, Birgit |e verfasserin |4 aut | |
| 700 | 1 | |a Drexel, Heinz |e verfasserin |4 aut | |
| 700 | 1 | |a Roden, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Schelkshorn, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Wascher, Thomas C |e verfasserin |4 aut | |
| 700 | 1 | |a Weitgasser, Raimund |e verfasserin |4 aut | |
| 700 | 1 | |a Zlamal-Fortunat, Sandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiener klinische Wochenschrift |d 1946 |g 135(2023), Suppl 1 vom: 27. Jan., Seite 32-44 |w (DE-627)NLM000045071 |x 1613-7671 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2023 |g number:Suppl 1 |g day:27 |g month:01 |g pages:32-44 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00508-023-02186-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2023 |e Suppl 1 |b 27 |c 01 |h 32-44 | ||